LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

Apollomics Announces Presentation at the 2024 BIO International Convention

May 29, 2024 | Last Trade: US$5.69 0.25 -4.21

FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

BIO International Convention (June 3-6, 2024)

Format: In-person
Location: San Diego, California
Presentation Date: Tuesday, June 4, 2024
Location: Theater 2 located in Hall A of the Exhibition Hall at the San Diego Convention Center
Presentation Time: 3:15 p.m.
Presenter: Sanjeev Redkar, PhD, President and Executive Director of Apollomics

Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact This email address is being protected from spambots. You need JavaScript enabled to view it..

About Apollomics Inc.

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com.

CONTACTS 
Investor Relations 
Peter Vozzo 
ICR Westwicke 
This email address is being protected from spambots. You need JavaScript enabled to view it. 
+1-443-213-0505 

Media Relations 
Sean Leous 
ICR Westwicke 
This email address is being protected from spambots. You need JavaScript enabled to view it. 
+1-646-866-4012 

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page